Table 3 Previous studies of various treatment modalities for submacular hemorrhange in neovascular age-related macular degeneration.
Study | Number of subjects | Study design | Treatment strategies | Baseline LogMAR, BCVA, mean (SD) | LogMAR Visual Outcome, mean (SD), follow-up period | Result |
|---|---|---|---|---|---|---|
Kim et al., 2014 | 91 | Retrospective, interventional | Intravitreal anti-VEGF | 1.38 (0.53) | 0.96 (0.65), 6 months | Beneficial |
Iacono et al., 2014 | 23 | Prospective, interventional | Intravitreal anti-VEGF | 0.82 (0.22) | 0.68 (0.41), 12 months | Beneficial |
Shin et al., 2015 | 82 | Retrospective, comparative, interventional | (1) Intravitreal anti-VEGF | 1.21 (0.71) | 0.76 (0.59), 6 months | Both are beneficial. Combination therapy was better in thick submacular hemorrhage. |
(2) Intravitreal anti-VEGF with pneumatic displacement | 1.14 (0.63) | 0.94 (0.61), 6 months | ||||
Cho et al., 2015 | 93 | Retrospective, comparative, interventional | (1) Intravitreal anti-VEGF | 1.18 (0.57) | 0.96 (0.39), 12 months | Both are beneficial. No difference between them |
(2) Intravitreal anti-VEGF with pneumatic displacement | 1.20 (0.74) | 0.95 (0.48), 12 months | ||||
Kitagawa et al., 2016 | 20 | Prospective, interventional | Intravitreal t-PA, anti-VEGF, and gas tamponade | 0.66 (0.40) | 0.42 (0.45), 6 months | Beneficial |
Kadonosono et al., 2015 | 13 | Prospective, interventional | Subretinal surgery with t-PA and gas tamponade | 1.21 (0.44) | 0.70 (0.33), 3 months | Beneficial |
Chang et al., 2014 | 101 | Retrospective, comparative, interventional | (1) Subretinal surgery with t-PA, gas tamponade, and intravitreal anti-VEGF | 1.92 (N/A) | 1.74 (N/A), 6 months | Both are beneficial. Anti-VEGF may help maintain the visual acuity gains. |
(2) Subretinal surgery with t-PA, gas tamponade | 2.26 (N/A) | 1.54 (N/A), 6 months | ||||
Jong et al., 2016 | 24 | Prospective, comparative, interventional | (1) Intravitreal t-PA, anti-VEGF, and gas tamponade | 0.91 (N/A) | 0.63 (N/A), 12 weeks | Both are beneficial. No difference between them |
(2) Subretinal surgery with t-PA, gas tamponade, and intravitreal anti-VEGF | 0.75 (N/A) | 0.72 (N/A), 12 weeks | ||||
Current study | 236 | Retrospective, comparative, interventional | (1) Observation | 1.57 (0.74) | 1.39 (0.84), 12 months | No differences among 4 treatment strageis. Intravitreal Anti-VEGF helped with visual recovery in the short term. |
(2) Intravitreal anti-VEGF | 1.09 (0.70) | 0.90 (0.83), 12 months | ||||
(3) Intravitrea gas tamponade(± anti-VEGF or t-PA) | 1.31 (0.83) | 1.35 (0.88), 12 months | ||||
(4) Subretinal surgery with t-PA, gas tamponade (± anti-VEGF) | 1.62 (0.77) | 1.44 (0.91), 12 months |
